Turnstone Biologics' rising cash burn and falling operating ...

Turnstone Biologics' rising cash burn and falling operating revenue is worrisome. Its high-risk status and potential for extreme dilution is due to the size of the cash burn relative to market value. Shareholders should closely monitor the company's cash usage.